David Denning is an infectious diseases clinician with expertise in fungal diseases. He has been a Professor of Infectious Diseases and Global Health at the University of Manchester since 2005.

From 2009 to 2020, David led the National Aspergillosis Centre, Manchester, a referral centre in the UK for all patients with chronic pulmonary aspergillosis.

His current academic interests are chronic and allergic pulmonary fungal disease, the global burden of fungal infection, resistance in Aspergillus and getting new antifungals developed. He has published over 600 scientific articles.

David leads LIFE (Leading International Fungal Education), which is focused on improving patient outcomes through online education. He was the founding Chief Executive of Global Action For Fungal Infections (2013–2023), based in Switzerland and the UK which advocates for access to fungal diagnostics and antifungal therapies. David is the founder of two biotechnology companies F2G Ltd. and Myconostica Ltd (now Lab21).

He graduated from Guys Hospital in 1980 and has trained in various specialities in London, Glasgow and Stanford, California.